Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.50 |
| ▸ | CTSS | P25774 | 3/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 4/20 | 0.48 |
| ▸ | PPARG | P37231 | 3/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 4/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | REN | P00797 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23834030 | 0.81 | PPARA (0.50) | CTSKCTSSAPPPPARAPPARG | |
| SCHEMBL23834032 | 0.81 | PPARA (0.50) | CTSKCTSSAPPPPARAPPARG | |
| SCHEMBL14636351 | 0.81 | CTSK (0.56) | CTSKCTSS | |
| SCHEMBL1414624 | 0.81 | CTSK (0.52) | CTSKCTSSAPPCTSLCTSB | |
| SCHEMBL24095807 | 0.80 | CTSK (0.47) | CTSK | |
| SCHEMBL30420278 | 0.80 | PSEN1 (0.49) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL8877994 | 0.79 | BCL2 (0.58) | CTSKCTSSCTSLCTSBREN | |
| SCHEMBL25410170 | 0.79 | CTSK (0.43) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL25410163 | 0.79 | CTSK (0.43) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL13050499 | 0.78 | ACE (0.58) | CTSKCTSSAPPPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES INC (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2021252640-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | ASNS, SI, NARS1 | CTSK 1960/4885CTSS 831/4885APP 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.